{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:10:44Z","timestamp":1792239044744,"version":"4.4.0"},"reference-count":76,"publisher":"Harborside Press, LLC","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>Immunotherapies have recently changed the treatment landscape of multiple myeloma (MM). CAR T cells and T-cell\u2013redirecting bispecific antibodies (BsAbs) yield impressive responses and extend survival in patients with relapsed\/refractory MM. There are now 2 BCMA-directed CAR T-cell products and 4 BsAbs (3 targeting BCMA, 1 targeting GPRC5D) currently approved by the FDA for relapsed\/refractory MM, in which they demonstrated considerable efficacy. These drugs are now being evaluated in early treatment settings, including as part of frontline regimens for newly diagnosed MM. Importantly, administration of CAR T-cell therapy and BsAbs necessitate careful attention to unique toxicities, including cytokine release syndrome, immune effector cell\u2013associated neurotoxicity syndrome, cytopenias, and heightened infection risk. This review summarizes the current landscape of immunotherapy in MM, including perspectives on sequencing CAR T-cell therapy and BsAbs. It also discusses ongoing clinical trials evaluating immunotherapy in new combinations and treatment contexts. Immunotherapies have become a key component of the MM therapeutic armamentarium and are poised to assume an even larger role in the coming years.<\/jats:p>","DOI":"10.6004\/jnccn.2026.7004","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T13:19:45Z","timestamp":1779801585000},"source":"Crossref","is-referenced-by-count":2,"title":["Incorporating the Next Generation of Immunotherapies Into the Treatment of Multiple Myeloma"],"prefix":"10.6004","volume":"24","author":[{"given":"Kevin C.","family":"Miller","sequence":"first","affiliation":[{"name":"Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross S.","family":"Firestone","sequence":"additional","affiliation":[{"name":"Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Hultcrantz","sequence":"additional","affiliation":[{"name":"Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"Blood","first-page":"936","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees PM","year":"2020","unstructured":"Voorhees PM, Kaufman JL, Laubach J,  Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood 2020;136:936\u2013945."},{"key":"B2","series-title":"N Engl J Med","first-page":"301","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld P","year":"2024","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M,  Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2024;390:301\u2013313."},{"key":"B3","series-title":"N Engl J Med","first-page":"1597","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon T","year":"2024","unstructured":"Facon T, Dimopoulos MA, Leleu XP,  Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2024;391:1597\u20131609."},{"key":"B4","series-title":"Blood","first-page":"4","article-title":"Results of the phase III randomized Iskia trial: isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients","volume":"142","author":"Gay F","year":"2023","unstructured":"Gay F, Roeloffzen W, Dimopoulos MA,  Results of the phase III randomized Iskia trial: isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients. Blood 2023;142(Suppl 1):4."},{"key":"B5","series-title":"J Clin Oncol","first-page":"1279","article-title":"Isatuximab, lenalidomide, bortezomib, and dexamethasone induction therapy for transplant-eligible newly diagnosed multiple myeloma: final part 1 analysis of the GMMG-HD7 trial","volume":"43","author":"Mai EK","year":"2025","unstructured":"Mai EK, Bertsch U, Pozek E,  Isatuximab, lenalidomide, bortezomib, and dexamethasone induction therapy for transplant-eligible newly diagnosed multiple myeloma: final part 1 analysis of the GMMG-HD7 trial. J Clin Oncol 2025;43:1279\u20131288."},{"key":"B6","series-title":"J Clin Oncol","first-page":"2901","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa LJ","year":"2022","unstructured":"Costa LJ, Chhabra S, Medvedova E,  Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J Clin Oncol 2022;40:2901\u20132912."},{"key":"B7","series-title":"JAMA Oncol","first-page":"862","article-title":"Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the MANHATTAN nonrandomized clinical trial","volume":"7","author":"Landgren O","year":"2021","unstructured":"Landgren O, Hultcrantz M, Diamond B,  Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the MANHATTAN nonrandomized clinical trial. JAMA Oncol 2021;7:862\u2013868."},{"key":"B8","series-title":"Hematology Am Soc Hematol Educ Program","first-page":"433","article-title":"A rational approach to functional high-risk myeloma","volume":"2023","author":"Gay F","year":"2023","unstructured":"Gay F, Bertuglia G, Mina R. A rational approach to functional high-risk myeloma. Hematology Am Soc Hematol Educ Program 2023;2023:433\u2013442."},{"key":"B9","series-title":"Br J Haematol","first-page":"1300","article-title":"Subsequent therapy and outcomes in patients with newly diagnosed multiple myeloma experiencing disease progression after quadruplet combinations","volume":"204","author":"Ravi G","year":"2024","unstructured":"Ravi G, Bal S, Joiner L,  Subsequent therapy and outcomes in patients with newly diagnosed multiple myeloma experiencing disease progression after quadruplet combinations. Br J Haematol 2024;204:1300\u20131306."},{"key":"B10","series-title":"N Engl J Med","first-page":"705","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi NC","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N,  Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 2021;384:705\u2013716."},{"key":"B11","series-title":"J Clin Oncol","first-page":"1265","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin T","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG,  Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol 2023;41:1265\u20131274."},{"key":"B12","series-title":"N Engl J Med","first-page":"495","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau P","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk N,  Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 2022;387:495\u2013505."},{"key":"B13","series-title":"N Engl J Med","first-page":"2232","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari A","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG,  Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med 2022;387:2232\u20132244."},{"key":"B14","series-title":"Nat Med","first-page":"2259","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin AM","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B,  Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med 2023;29:2259\u20132267."},{"key":"B15","series-title":"J Clin Oncol","first-page":"2702","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma N","year":"2024","unstructured":"Bumma N, Richter J, Jagannath S,  Linvoseltamab for treatment of relapsed\/refractory multiple myeloma. J Clin Oncol 2024;42:2702\u20132712."},{"key":"B16","series-title":"J Clin Oncol","first-page":"2766","article-title":"Long-term (\u22655-Year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma","volume":"43","author":"Jagannath S","year":"2025","unstructured":"Jagannath S, Martin TG, Lin Y,  Long-term (\u22655-Year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma. J Clin Oncol 2025;43:2766\u20132771."},{"key":"B17","series-title":"N Engl J Med.","article-title":"Teclistamab plus daratumumab in relapsed or refractory multiple myeloma","author":"Costa LJ","unstructured":"Costa LJ, Bahlis NJ, Perrot A,  Teclistamab plus daratumumab in relapsed or refractory multiple myeloma. N Engl J Med. Published online December 9, 2025. doi:10.1056\/NEJMoa2514663"},{"key":"B18","series-title":"Nat Rev Clin Oncol","first-page":"590","article-title":"Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins","volume":"21","author":"Neri P","year":"2024","unstructured":"Neri P, Leblay N, Lee H,  Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins. Nat Rev Clin Oncol 2024;21:590\u2013609."},{"key":"B19","series-title":"Front Oncol","first-page":"1398902","article-title":"Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma","volume":"14","author":"Miller K","year":"2024","unstructured":"Miller K, Hashmi H, Rajeeve S. Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma. Front Oncol 2024;14:1398902."},{"key":"B20","series-title":"N Engl J Med","first-page":"393","article-title":"Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma","volume":"391","author":"Hungria V","year":"2024","unstructured":"Hungria V, Robak P, Hus M,  Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 2024;391:393\u2013407."},{"key":"B21","series-title":"N Engl J Med","first-page":"408","article-title":"Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma","volume":"391","author":"Dimopoulos MA","year":"2024","unstructured":"Dimopoulos MA, Beksac M, Pour L,  Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma. N Engl J Med 2024;391:408\u2013421."},{"key":"B22","series-title":"Nat Rev Immunol","first-page":"651","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman AD","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol 2020;20:651\u2013668."},{"key":"B23","series-title":"Lancet Haematol","first-page":"e459","article-title":"Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial","volume":"6","author":"Mateos MV","year":"2019","unstructured":"Mateos MV, Blacklock H, Schjesvold F,  Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Lancet Haematol 2019;6:e459\u2013469."},{"key":"B24","series-title":"Lancet Haematol","first-page":"e448","article-title":"Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial","volume":"6","author":"Usmani SZ","year":"2019","unstructured":"Usmani SZ, Schjesvold F, Oriol A,  Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial. Lancet Haematol 2019;6:e448\u2013458."},{"key":"B25","series-title":"Sci Transl Med","first-page":"eaau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith EL","year":"2019","unstructured":"Smith EL, Harrington K, Staehr M,  GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med 2019;11:eaau7746."},{"key":"B26","series-title":"Clin Cancer Res","first-page":"2048","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter RO","year":"2013","unstructured":"Carpenter RO, Evbuomwan MO, Pittaluga S,  B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res 2013;19:2048\u20132060."},{"key":"B27","series-title":"Nat Rev Drug Discov","first-page":"301","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein C","year":"2024","unstructured":"Klein C, Brinkmann U, Reichert JM, Kontermann RE. The present and future of bispecific antibodies for cancer therapy. Nat Rev Drug Discov 2024;23:301\u2013319."},{"key":"B28","series-title":"N Engl J Med","first-page":"1726","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje N","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y,  Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med 2019;380:1726\u20131737."},{"key":"B29","series-title":"N Engl J Med","first-page":"1002","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero P","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B,  Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med 2023;388:1002\u20131014."},{"key":"B30","series-title":"Transplant Cell Ther","first-page":"S404","article-title":"Long-term benefits in patient-reported outcomes and time to next anti-myeloma therapy of ciltacabtagene autoleucel (cilta-cel) versus standard of care for patients with lenalidomide-refractory multiple myeloma: results from the phase 3 Cartitude-4 clinical trial","volume":"31","author":"Bar N","year":"2025","unstructured":"Bar N, Mina R, Mylin AK,  Long-term benefits in patient-reported outcomes and time to next anti-myeloma therapy of ciltacabtagene autoleucel (cilta-cel) versus standard of care for patients with lenalidomide-refractory multiple myeloma: results from the phase 3 Cartitude-4 clinical trial. Transplant Cell Ther 2025;31:S404\u2013405."},{"key":"B31","series-title":"N Engl J Med","first-page":"335","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel J","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K,  Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med 2023;389:335\u2013347."},{"key":"B32","series-title":"Nat Med","first-page":"2132","article-title":"Noncanonical and mortality-defining toxicities of CAR T cell therapy","volume":"31","author":"Rejeski K","year":"2025","unstructured":"Rejeski K, Hill JA, Dahiya S, Jain MD. Noncanonical and mortality-defining toxicities of CAR T cell therapy. Nat Med 2025;31:2132\u20132146."},{"key":"B33","series-title":"Cancers (Basel)","first-page":"282","article-title":"Comprehensive review of early and late toxicities in CAR T-cell therapy and bispecific antibody treatments for hematologic malignancies","volume":"17","author":"Bangolo A","year":"2025","unstructured":"Bangolo A, Amoozgar B, Mansour C,  Comprehensive review of early and late toxicities in CAR T-cell therapy and bispecific antibody treatments for hematologic malignancies. Cancers (Basel) 2025;17:282."},{"key":"B34","series-title":"Transplant Cell Ther","first-page":"955","article-title":"Best practice considerations by The American Society of Transplant and Cellular Therapy: infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies","volume":"30","author":"Shahid Z","year":"2024","unstructured":"Shahid Z, Jain T, Dioverti V,  Best practice considerations by The American Society of Transplant and Cellular Therapy: infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies. Transplant Cell Ther 2024;30:955\u2013969."},{"key":"B35","series-title":"Blood Cancer J","first-page":"180","article-title":"Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma","volume":"14","author":"Fortuna GG","year":"2024","unstructured":"Fortuna GG, Banerjee R, Savid-Frontera C,  Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma. Blood Cancer J 2024;14:180."},{"key":"B36","series-title":"N Engl J Med","first-page":"577","article-title":"CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in TP53","volume":"392","author":"Perica K","year":"2025","unstructured":"Perica K, Jain N, Scordo M,  CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in TP53. N Engl J Med 2025;392:577\u2013583."},{"key":"B37","series-title":"Blood","first-page":"1243","article-title":"Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells","volume":"142","author":"Karschnia P","year":"2023","unstructured":"Karschnia P, Miller KC, Yee AJ,  Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells. Blood 2023;142:1243\u20131248."},{"key":"B38","series-title":"Lancet Oncol","first-page":"e374","article-title":"Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee","volume":"25","author":"Lin Y","year":"2024","unstructured":"Lin Y, Qiu L, Usmani S,  Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee. Lancet Oncol 2024;25:e374\u2013387."},{"key":"B39","series-title":"Blood Adv","first-page":"768","article-title":"Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma","volume":"7","author":"Frigault MJ","year":"2023","unstructured":"Frigault MJ, Bishop MR, Rosenblatt J,  Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma. Blood Adv 2023;7:768\u2013777."},{"key":"B40","series-title":"Nat Med","first-page":"422","article-title":"Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results","volume":"29","author":"Mailankody S","year":"2023","unstructured":"Mailankody S, Matous JV, Chhabra S,  Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nat Med 2023;29:422\u2013429."},{"key":"B41","series-title":"N Engl J Med","first-page":"1196","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody S","year":"2022","unstructured":"Mailankody S, Devlin SM, Landa J,  GPRC5D-targeted CAR T cells for myeloma. N Engl J Med 2022;387:1196\u20131206."},{"key":"B42","series-title":"Blood Cancer Discov","first-page":"146","article-title":"Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma","volume":"1","author":"Fernandez de Larrea C","year":"2020","unstructured":"Fernandez de Larrea C, Staehr M, Lopez AV,  Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma. Blood Cancer Discov 2020;1:146\u2013154."},{"key":"B43","series-title":"Mol Cancer Ther","first-page":"2008","article-title":"Preclinical efficacy and safety comparison of CD3 bispecific and ADC modalities targeting BCMA for the treatment of multiple myeloma","volume":"18","author":"Panowski SH","year":"2019","unstructured":"Panowski SH, Kuo TC, Zhang Y,  Preclinical efficacy and safety comparison of CD3 bispecific and ADC modalities targeting BCMA for the treatment of multiple myeloma. Mol Cancer Ther 2019;18:2008\u20132020."},{"key":"B44","series-title":"J Clin Oncol","first-page":"3576","article-title":"A phase I first-in-human study of ABBV-383, a B-cell maturation antigen x CD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma","volume":"40","author":"D\u2019Souza A","year":"2022","unstructured":"D\u2019Souza A, Shah N, Rodriguez C,  A phase I first-in-human study of ABBV-383, a B-cell maturation antigen x CD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma. J Clin Oncol 2022;40:3576\u20133586."},{"key":"B45","series-title":"J Clin Oncol","first-page":"7517","article-title":"Longer-term follow-up of patients (pts) receiving prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) in the phase 1\/2 MajesTEC-1 study of teclistamab in relapsed\/refractory multiple myeloma (RRMM)","volume":"42(Suppl)","author":"van de Donk NWCJ","year":"2024","unstructured":"van de Donk NWCJ, Garfall AL, Benboubker L,  Longer-term follow-up of patients (pts) receiving prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) in the phase 1\/2 MajesTEC-1 study of teclistamab in relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol 2024;42(Suppl):Abstract 7517."},{"key":"B46","series-title":"Blood Adv","article-title":"IVIG prophylaxis should be initiated following bispecific antibody therapy in multiple myeloma regardless of IgG levels","author":"Banerjee R","year":"2025","unstructured":"Banerjee R, Mohan M, Rejeski K,  IVIG prophylaxis should be initiated following bispecific antibody therapy in multiple myeloma regardless of IgG levels. Blood Adv 2025;9:4720\u20134726."},{"key":"B47","series-title":"Blood Cancer J","first-page":"116","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje N","year":"2023","unstructured":"Raje N, Anderson K, Einsele H,  Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood Cancer J 2023;13:116."},{"key":"B48","series-title":"Blood Cancer J","first-page":"137","article-title":"Sustained remission following finite duration bispecific antibody therapy in patients with relapsed\/refractory myeloma","volume":"14","author":"Chakraborty R","year":"2024","unstructured":"Chakraborty R, Cheruvalath H, Patwari A,  Sustained remission following finite duration bispecific antibody therapy in patients with relapsed\/refractory myeloma. Blood Cancer J 2024;14:137."},{"key":"B49","series-title":"Blood Cancer Discov","first-page":"388","article-title":"T cell-redirecting bispecific antibodies in multiple myeloma: optimal dosing schedule and duration of treatment","volume":"5","author":"van de Donk N","year":"2024","unstructured":"van de Donk N, Rasche L, Sidana S,  T cell-redirecting bispecific antibodies in multiple myeloma: optimal dosing schedule and duration of treatment. Blood Cancer Discov 2024;5:388\u2013399."},{"key":"B50","series-title":"J Clin Oncol","first-page":"8034","article-title":"Durability of responses with biweekly dosing of teclistamab in patients with relapsed\/refractory multiple myeloma achieving a clinical response in the majesTEC-1 study","volume":"41","author":"Usmani SZ","year":"2023","unstructured":"Usmani SZ, Karlin L, Benboubker L,  Durability of responses with biweekly dosing of teclistamab in patients with relapsed\/refractory multiple myeloma achieving a clinical response in the majesTEC-1 study. J Clin Oncol 2023;41:8034\u20138034."},{"key":"B51","series-title":"Cancer Manag Res","first-page":"743","article-title":"Perspectives on talquetamab and its utility in the treatment of multiple myeloma: safety, efficacy and place in therapy","volume":"17","author":"Miller KC","year":"2025","unstructured":"Miller KC, Hamadeh I, Tan CR. Perspectives on talquetamab and its utility in the treatment of multiple myeloma: safety, efficacy and place in therapy. Cancer Manag Res 2025;17:743\u2013756."},{"key":"B52","series-title":"Blood","first-page":"1934","article-title":"Depletion of mature B cells and of normal plasma cells (PC) behind the higher incidence of infections after anti-BCMA vs Anti-GPRC5D bispecific antibodies (bsAb) in relapsed refractory multiple myeloma (RRMM)","volume":"144(Suppl 1)","author":"Jelinek T","year":"2024","unstructured":"Jelinek T, Zihala D, Zabaleta A,  Depletion of mature B cells and of normal plasma cells (PC) behind the higher incidence of infections after anti-BCMA vs Anti-GPRC5D bispecific antibodies (bsAb) in relapsed refractory multiple myeloma (RRMM). Blood 2024;144(Suppl 1):1934."},{"key":"B53","series-title":"Blood Adv","first-page":"3069","article-title":"Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis","volume":"7","author":"Mazahreh F","year":"2023","unstructured":"Mazahreh F, Mazahreh L, Schinke C,  Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis. Blood Adv 2023;7:3069\u20133074."},{"key":"B54","series-title":"Blood","first-page":"1021","article-title":"Cevostamab in patients with heavily pretreated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study demonstrate clinically meaningful activity and manageable safety and inform the doses and regimen for combination studies","volume":"144(Suppl 1)","author":"Richter J","year":"2024","unstructured":"Richter J, Thomas SK, Krishnan AY,  Cevostamab in patients with heavily pretreated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study demonstrate clinically meaningful activity and manageable safety and inform the doses and regimen for combination studies. Blood 2024;144(Suppl 1):1021."},{"key":"B55","series-title":"Lancet Oncol","first-page":"207","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial S","year":"2020","unstructured":"Lonial S, Lee HC, Badros A,  Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol 2020;21:207\u2013221."},{"key":"B56","series-title":"Mol Cancer Ther","first-page":"1941","article-title":"Belantamab mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated antitumor responses in vivo","volume":"20","author":"Montes de Oca R","year":"2021","unstructured":"Montes de Oca R, Alavi AS, Vitali N,  Belantamab mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated antitumor responses in vivo. Mol Cancer Ther 2021;20:1941\u20131955."},{"key":"B57","series-title":"Blood Neoplasia","first-page":"100103","article-title":"Belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: a real-world experience","volume":"2","author":"Hultcrantz M","year":"2025","unstructured":"Hultcrantz M, Derkach A, Hassoun H,  Belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: a real-world experience. Blood Neoplasia 2025;2:100103."},{"key":"B58","series-title":"Blood","first-page":"2000.2","article-title":"A phase I\/II study of AZD0305, a novel antibody-drug conjugate (ADC) targeting GPRC5D, in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"144(Suppl 1)","author":"Lim SL","year":"2024","unstructured":"Lim SL, Augustson B, Mian HS,  A phase I\/II study of AZD0305, a novel antibody-drug conjugate (ADC) targeting GPRC5D, in patients with relapsed\/refractory multiple myeloma (RRMM). Blood 2024;144(Suppl 1):2000.2."},{"key":"B59","series-title":"Nat Commun","first-page":"868","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur MK","year":"2021","unstructured":"Samur MK, Fulciniti M, Aktas Samur A,  Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun 2021;12:868."},{"key":"B60","series-title":"Blood","first-page":"402","article-title":"Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma","volume":"144","author":"Firestone RS","year":"2024","unstructured":"Firestone RS, Socci ND, Shekarkhand T,  Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma. Blood 2024;144:402\u2013407."},{"key":"B61","series-title":"Nat Med","first-page":"2295","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee H","year":"2023","unstructured":"Lee H, Ahn S, Maity R,  Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med 2023;29:2295\u20132306."},{"key":"B62","series-title":"Leukemia","first-page":"543","article-title":"International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma","volume":"39","author":"Costa LJ","year":"2025","unstructured":"Costa LJ, Banerjee R, Mian H,  International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma. Leukemia 2025;39:543\u2013554."},{"key":"B63","series-title":"Blood","first-page":"2063","article-title":"Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T cell therapy","volume":"146","author":"Dhakal B","year":"2025","unstructured":"Dhakal B, Akhtar OS, Fandrei D,  Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T cell therapy. Blood 2025;146:2063\u20132072."},{"key":"B64","series-title":"Blood Cancer J","first-page":"214","article-title":"Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy","volume":"14","author":"Merz M","year":"2024","unstructured":"Merz M, Dima D, Hashmi H,  Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy. Blood Cancer J 2024;14:214."},{"key":"B65","series-title":"Blood","first-page":"1948","article-title":"Co-expression of GPRC5D, FcRH5 and BCMA suggests that targeting more than one cell surface marker may be a viable strategy in relapsed\/refractory multiple myeloma (RRMM): biomarker results from the phase I study of forimtamig, a GPRC5DxCD3 bispecific antibody","volume":"142(Suppl 1)","author":"Dekhtiarenko I","year":"2023","unstructured":"Dekhtiarenko I, Lelios I, Jacob W,  Co-expression of GPRC5D, FcRH5 and BCMA suggests that targeting more than one cell surface marker may be a viable strategy in relapsed\/refractory multiple myeloma (RRMM): biomarker results from the phase I study of forimtamig, a GPRC5DxCD3 bispecific antibody. Blood 2023;142(Suppl 1):1948."},{"key":"B66","series-title":"J Clin Oncol","first-page":"7505","article-title":"First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): initial phase 1 results","volume":"43(Suppl)","author":"NWCJvd D","year":"2025","unstructured":"NWCJvd D, Vega G, Perrot A,  First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): initial phase 1 results. J Clin Oncol 2025;43(Suppl):Abstract 7505."},{"key":"B67","series-title":"Nat Cancer","first-page":"1494","article-title":"ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells","volume":"5","author":"Carretero-Iglesia L","year":"2024","unstructured":"Carretero-Iglesia L, Hall OJ, Berret J,  ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells. Nat Cancer 2024;5:1494\u20131514."},{"key":"B68","series-title":"N Engl J Med","first-page":"138","article-title":"Talquetamab plus teclistamab in relapsed or refractory multiple myeloma","volume":"392","author":"Cohen YC","year":"2025","unstructured":"Cohen YC, Magen H, Gatt M,  Talquetamab plus teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 2025;392:138\u2013149."},{"key":"B69","series-title":"Blood","first-page":"493.","article-title":"Phase 2 study of teclistamab-based induction regimens in patients with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): results from the GMMG-HD10\/DSMM-XX (MajesTEC-5) trial","volume":"144(Suppl 1)","author":"Raab MS","year":"2024","unstructured":"Raab MS, Weinhold N, Kort\u00fcm KM,  Phase 2 study of teclistamab-based induction regimens in patients with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): results from the GMMG-HD10\/DSMM-XX (MajesTEC-5) trial. Blood 2024;144(Suppl 1):493."},{"key":"B70","series-title":"J Clin Oncol","first-page":"7506","article-title":"Safety results from the phase 3 MajesTEC-7 study in patients (pts) with transplant ineligible\/not intended newly diagnosed multiple myeloma (NDMM)","volume":"42(Suppl)","author":"Touzeau C","year":"2024","unstructured":"Touzeau C, Beksac M, Terpos E,  Safety results from the phase 3 MajesTEC-7 study in patients (pts) with transplant ineligible\/not intended newly diagnosed multiple myeloma (NDMM). J Clin Oncol 2024;42(Suppl):Abstract 7506."},{"key":"B71","series-title":"Nat Rev Cancer","first-page":"867","article-title":"New horizons in our understanding of precursor multiple myeloma and early interception","volume":"24","author":"Cordas Dos Santos DM","year":"2024","unstructured":"Cordas Dos Santos DM, Toenges R, Bertamini L,  New horizons in our understanding of precursor multiple myeloma and early interception. Nat Rev Cancer 2024;24:867\u2013886."},{"key":"B72","series-title":"Blood","first-page":"206.","article-title":"Immuno-PRISM: a randomized phase II platform study of bispecific antibodies in high-risk smoldering myeloma","volume":"142(Suppl 1)","author":"Nadeem O","year":"2023","unstructured":"Nadeem O, Magidson S, Midha S,  Immuno-PRISM: a randomized phase II platform study of bispecific antibodies in high-risk smoldering myeloma. Blood 2023;142(Suppl 1):206."},{"key":"B73","series-title":"Blood","first-page":"1027.","article-title":"Early safety and efficacy of CAR-T cell therapy in precursor myeloma: results of the CAR-PRISM study using ciltacabtagene autoleucel in high-risk smoldering myeloma","volume":"144(Suppl 1)","author":"Nadeem O","year":"2024","unstructured":"Nadeem O, Nikiforow S, DeBraganca K,  Early safety and efficacy of CAR-T cell therapy in precursor myeloma: results of the CAR-PRISM study using ciltacabtagene autoleucel in high-risk smoldering myeloma. Blood 2024;144(Suppl 1):1027."},{"key":"B74","series-title":"Blood","first-page":"1041","article-title":"Immune alterations in myeloma evolution and outcomes: quo vadis?","volume":"146","author":"Dhodapkar MV","year":"2025","unstructured":"Dhodapkar MV, Paiva B. Immune alterations in myeloma evolution and outcomes: quo vadis? Blood 2025;146:1041\u20131050."},{"key":"B75","series-title":"Blood Adv","first-page":"5873","article-title":"Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level","volume":"6","author":"Schinke C","year":"2022","unstructured":"Schinke C, Poos AM, Bauer M,  Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level. Blood Adv 2022;6:5873\u20135883."},{"key":"B76","series-title":"Haematologica","first-page":"2420","article-title":"Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible","volume":"109","author":"Engelhardt M","year":"2024","unstructured":"Engelhardt M, Kortum KM, Goldschmidt H, Merz M. Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible. Haematologica 2024;109:2420\u20132435."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/8\/article-e267004.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/8\/article-e267004.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/8\/article-e267004.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:55:54Z","timestamp":1786971354000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/8\/article-e267004.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":76,"journal-issue":{"issue":"8"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2026.7004","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]}}}